{"id":655457,"date":"2023-06-14T08:02:01","date_gmt":"2023-06-14T08:02:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=655457"},"modified":"2023-06-14T08:02:01","modified_gmt":"2023-06-14T08:02:01","slug":"lupus-nephritis-market-to-register-incremental-growth-during-the-forecast-period-20222032-asserts-delveinsight-key-companies-novartis-remegen-roche-annexon-argenx-astrazeneca-aurinia","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/lupus-nephritis-market-to-register-incremental-growth-during-the-forecast-period-20222032-asserts-delveinsight-key-companies-novartis-remegen-roche-annexon-argenx-astrazeneca-aurinia_655457.html","title":{"rendered":"Lupus Nephritis Market to Register Incremental Growth During the Forecast Period (2022-2032), Asserts DelveInsight | Key Companies – Novartis, RemeGen, Roche, Annexon, Argenx, AstraZeneca, Aurinia"},"content":{"rendered":"
\n
\"Lupus<\/a><\/div>\n
\n
Delveinsight Business Research LLP<\/div>\n<\/div>\n<\/div>\n
The Lupus Nephritis market size was USD 1,577.8 million in 2021, which is expected to rise during the study period (2019\u20132032). As per DelveInsight, the Lupus Nephritis Market is anticipated to evolve immensely in the coming years owing to the rising prevalent population of Lupus Nephritis in the 7MM and the launch of novel therapies in the market.<\/div>\n

DelveInsight’s “Lupus Nephritis Market Insights, Epidemiology, and Market Forecast 2032<\/strong>” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Lupus Nephritis market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).<\/p>\n

The report covers emerging Lupus Nephritis drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current Lupus Nephritis treatment practice\/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. <\/p>\n

\"Lupus<\/p>\n

Lupus Nephritis: An Overview<\/strong><\/p>\n

As per the National Kidney Foundation (NKF), there are two types of lupus. Systemic lupus erythematosus (SLE) is a form of lupus that can harm the skin, joints, kidneys, and brain and can be fatal. The other form of lupus is called “discoid” lupus erythematosus, which affects only the skin. When Systemic lupus erythematosus affects the kidneys, it is called lupus nephritis (LN).<\/p>\n

Systemic lupus erythematosus is a prototypic autoimmune disease and is the most common form of lupus that can affect multiple tissues and organs. The disease is characterized by the production of antibodies to components of the cell nucleus in association with a diverse array of clinical manifestations.<\/p>\n

Lupus Nephritis is a common and potentially devastating manifestation of Systemic lupus erythematosus. It is a leading cause of morbidity and mortality in patients with Systemic lupus erythematosus. Lupus nephritis leads to inflammation of small blood vessels, which play an important role in filtering waste materials in the kidney. It also involves the inflammation of glomeruli. Common signs of Lupus Nephritis are hematuria, proteinuria, edema, and sudden weight gain.<\/p>\n

Lupus Nephritis Market Key Facts<\/strong><\/p>\n